Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Zhang YW, Wang B, An SY, Liu WH, Wang C, Yan H, Xu YL, Wang YZ, Jia WQ. Clinical management and prognosis of spinal myxopapillary ependymoma: a single-institution cohort of 72 patients. Eur Spine J 2023;32:2459-2467. [PMID: 37027035 DOI: 10.1007/s00586-023-07690-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Revised: 03/12/2023] [Accepted: 03/24/2023] [Indexed: 04/08/2023]

For:	Zhang YW, Wang B, An SY, Liu WH, Wang C, Yan H, Xu YL, Wang YZ, Jia WQ. Clinical management and prognosis of spinal myxopapillary ependymoma: a single-institution cohort of 72 patients. Eur Spine J 2023;32:2459-2467. [PMID: 37027035 DOI: 10.1007/s00586-023-07690-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Revised: 03/12/2023] [Accepted: 03/24/2023] [Indexed: 04/08/2023]

Number

Cited by Other Article(s)

Wang C, Rooney MK, Alvarez-Breckenridge C, Beckham TH, Chung C, De BS, Ghia AJ, Grosshans D, Majd NK, McAleer MF, McGovern SL, North RY, Paulino AC, Perni S, Reddy JP, Rhines LD, Swanson TA, Tatsui CE, Tom MC, Yeboa DN, Li J. Outcomes and Pattern of Care for Spinal Myxopapillary Ependymoma in the Modern Era-A Population-Based Observational Study. Cancers (Basel) 2024;16:2013. [PMID: 38893133 PMCID: PMC11171081 DOI: 10.3390/cancers16112013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2024] [Revised: 05/18/2024] [Accepted: 05/23/2024] [Indexed: 06/21/2024] Open

Affiliation(s)

Chenyang Wang Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Michael K. Rooney Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Christopher Alvarez-Breckenridge Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA (L.D.R.)
Thomas H. Beckham Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Caroline Chung Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Brian S. De Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Amol J. Ghia Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
David Grosshans Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Nazanin K. Majd Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Mary F. McAleer Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Susan L. McGovern Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Robert Y. North Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA (L.D.R.)
Arnold C. Paulino Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Subha Perni Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Jay P. Reddy Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Laurence D. Rhines Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA (L.D.R.)
Todd A. Swanson Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Claudio E. Tatsui Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA (L.D.R.)
Martin C. Tom Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Debra N. Yeboa Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)
Jing Li Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; (M.K.R.); (D.G.); (A.C.P.); (M.C.T.); (J.L.)

Collapse

Song C, Kim HS, Lee JH, Yoon YC, Lee S, Lee SH, Kim ES. Development of a novel prediction model for differential diagnosis between spinal myxopapillary ependymoma and schwannoma. Sci Rep 2024;14:149. [PMID: 38167614 PMCID: PMC10762031 DOI: 10.1038/s41598-023-50806-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 12/26/2023] [Indexed: 01/05/2024] Open

Abstract

Spinal myxopapillary ependymoma (MPE) and schwannoma represent clinically distinct intradural extramedullary tumors, albeit with shared and overlapping magnetic resonance imaging (MRI) characteristics. We aimed to identify significant MRI features that can differentiate between MPE and schwannoma and develop a novel prediction model using these features. In this study, 77 patients with MPE (n = 24) or schwannoma (n = 53) who underwent preoperative MRI and surgical removal between January 2012 and December 2022 were included. MRI features, including intratumoral T2 dark signals, subarachnoid hemorrhage (SAH), leptomeningeal seeding, and enhancement patterns, were analyzed. Logistic regression analysis was conducted to distinguish between MPE and schwannomas based on MRI parameters, and a prediction model was developed using significant MRI parameters. The model was validated internally using a stratified tenfold cross-validation. The area under the curve (AUC) was calculated based on the receiver operating characteristic curve analysis. MPEs had a significantly larger mean size (p = 0.0035), higher frequency of intratumoral T2 dark signals (p = 0.0021), associated SAH (p = 0.0377), and leptomeningeal seeding (p = 0.0377). Focal and diffuse heterogeneous enhancement patterns were significantly more common in MPEs (p = 0.0049 and 0.0038, respectively). Multivariable analyses showed that intratumoral T2 dark signal (p = 0.0439) and focal (p = 0.0029) and diffuse enhancement patterns (p = 0.0398) were independent factors. The prediction model showed an AUC of 0.9204 (95% CI 0.8532-0.9876) and the average AUC for internal validation was 0.9210 (95% CI 0.9160-0.9270). MRI provides useful data for differentiating spinal MPEs from schwannomas. The prediction model developed based on the MRI features demonstrated excellent discriminatory performance.

Collapse